HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kanter, M. Z. Search for Related Content PubMed PubMed Citation Articles by Kanter, M. Z.

MICHELE ZELL KANTER, PHARM.D., is Coordinator, Toxikon Consortium, Section of Clinical Toxicology, Division of Occupational Medicine, Cook County Hospital, 1900 West Polk Street, Suite 500, Chicago, IL 60612 (nkanter{at}aol.com).

Purpose. The efficacy, safety, and cost issues that should be considered when deciding on the appropriate route of acetylcysteine for the treatment of patients with acetaminophen poisoning are reviewed. Summary. Oral and i.v. acetylcysteine appear to be equally effective when given within 8–10 hours of acetaminophen overdose. Anaphylactoid reactions to i.v. acetylcysteine have generally been reported in 3–6% of acetaminophen-poisoned patients. Dosing errors and hyponatremia have occurred in pediatric patients receiving i.v. acetylcysteine. Several investigators found an increased rate of anaphylactoid reactions in patients treated with i.v. acetylcysteine whose pretreatment serum acetaminophen levels were nontoxic. Compounding i.v. acetylcysteine from the oral preparation is less expensive than using premade i.v. solution. State pharmacy laws dictate whether extemporaneous compounding of acetylcysteine from the oral formulation is allowed. Oral acetylcysteine administration has resulted in minimal anaphylactoid reactions and is safer than i.v. acetylcysteine. Oral therapy should preferentially be considered in patients with asthma or atopic histories. The most important factors to consider when selecting the route of acetylcysteine administration include individual susceptibility, the severity of acetaminophen toxicity, and the time interval between acetaminophen ingestion and initiation of acetylcysteine therapy. Conclusion. Oral acetylcysteine administered within 8–10 hours of acetaminophen overdose prevents liver toxicity in the majority of patients who tolerate it and have no contraindications to therapy. I.V. acetylcysteine should be administered when patients are treated more than 10 hours postingestion of acetaminophen overdose or have underlying conditions preventing oral treatment. Anaphylactoid reactions are rare and occur more frequently in patients treated with the i.v. preparation. Index terms: Acetaminophen; Acetylcysteine; Allergies; Analgesics and antipyretics; Anaphylaxis; Antidotes; Blood levels; Contraindications; Costs; Dosage; Dosage schedules; Drug administration routes; Drugs, adverse reactions; Liver diseases; Pediatrics; Pharmacoeconomics; Placental transfer; Poisoning; Pregnancy; Protocols; Toxicity

 

This article has been cited by other articles:

				P. M. Alapat and J. L. Zimmerman Toxicology in the Critical Care Unit Chest, April 1, 2008; 133(4): 1006 - 1013. [Abstract] [Full Text] [PDF]

				R. Siden and C. E. Johnson Stability of a flavored formulation of acetylcysteine for oral administration Am. J. Health Syst. Pharm., March 15, 2008; 65(6): 558 - 561. [Abstract] [Full Text] [PDF]

				L. F. Ferreira and M. B. Reid Muscle-derived ROS and thiol regulation in muscle fatigue J Appl Physiol, March 1, 2008; 104(3): 853 - 860. [Abstract] [Full Text] [PDF]